Miroslav Mareš

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 177 citations · Full text

Neurological Disorder, Phase 2B, Clinical Trials +7

Approaches to spondylotic cervical myelopathy: conservative versus surgical results in a 3-year follow-up study.

Zdeněk Kadaňka, Miroslav Mareš, Josef Bednaník et al. · PubMed · 2002 · 157 citations

Predictive factors for mild forms of spondylotic cervical myelopathy treated conservatively or surgically

Zdeněk Kadaňka, Miroslav Mareš, Josef Bednařík et al. · European Journal of Neurology · 2004 · 62 citations

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán et al. · Multiple Sclerosis Journal · 2021 · 59 citations · Full text

Predictive factors for spondylotic cervical myelopathy treated conservatively or surgically

Zdeněk Kadaňka, Miroslav Mareš, Josef Bednařík et al. · European Journal of Neurology · 2004 · 56 citations